European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
The European Medicines Agency wants to accelerate clinical development plans with new processes and procedures in 2016 and companies must disclose payments to providers starting mid-year; Ireland and Switzerland look set to grapple with high drug prices, and France's industry wants to reverse the erosion of jobs.
You may also be interested in...
'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context
EMA official gives perspectives on how PRIME and adaptive pathways compare, and how they fit with other programs such as conditional authorization.
EMA Head On Transparency, Affordable Innovation, And What Patients Really Need
EMA will reinforce its role as a global reference authority and help build regulatory capacity in less experienced countries, Guido Rasi says in outlining his five-year priorities for the agency. He hopes regulatory efficiencies might contribute to lower drug prices.
Demand Soars For Parallel EMA-HTA Advice
Number of parallel review procedures thus far in 2015 nears total for previous five years combined.